Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
Evidence found in paper:
"the r code used to generate the results in this publication are freely available from our github: https://github com/erasmusmc-bioinformatics/tmz-analysis under the gnu general public license v 3 0."
COI Disclosure
Evidence found in paper:
"Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding This project was funded by the Foundation STOPbraintumors, the Erasmus MC Human Disease Model Award 2018 and the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie ITN initiative (Grant Agreement # 766069)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025